Francia Pietro, Ricotta Agnese, Frattari Alessandra, Stanzione Rosita, Modestino Anna, Mercanti Federico, Adduci Carmen, Sensini Isabella, Cotugno Maria, Balla Cristina, Rubattu Speranza, Volpe Massimo
Cardiology, Department of Clinical and Molecular Medicine, St. Andrea Hospital, Sapienza University, Rome, Italy.
Clin Med Insights Cardiol. 2013 Sep 15;7:153-9. doi: 10.4137/CMC.S12239. eCollection 2013.
Atrial natriuretic peptide (ANP) has antihypertrophic and antifibrotic properties that are relevant to AF substrates. The -G664C and rs5065 ANP single nucleotide polymorphisms (SNP) have been described in association with clinical phenotypes, including hypertension and left ventricular hypertrophy. A recent study assessed the association of early AF and rs5065 SNPs in low-risk subjects. In a Caucasian population with moderate-to-high cardiovascular risk profile and structural AF, we conducted a case-control study to assess whether the ANP -G664C and rs5065 SNP associate with nonfamilial structural AF.
168 patients with nonfamilial structural AF and 168 age- and sex-matched controls were recruited. The rs5065 and -G664C ANP SNPs were genotyped.
The study population had a moderate-to-high cardiovascular risk profile with 86% having hypertension, 23% diabetes, 26% previous myocardial infarction, and 23% left ventricular systolic dysfunction. Patients with AF had greater left atrial diameter (44 ± 7 vs. 39 ± 5 mm; P < 0.001) and higher plasma NTproANP levels (6240 ± 5317 vs. 3649 ± 2946 pmol/mL; P < 0.01). Odds ratios (ORs) for rs5065 and -G664C gene variants were 1.1 (95% confidence interval [CI], 0.7-1.8; P = 0.71) and 1.2 (95% CI, 0.3-3.2; P = 0.79), respectively, indicating no association with AF. There were no differences in baseline clinical characteristics among carriers and noncarriers of the -664C and rs5065 minor allele variants.
We report lack of association between the rs5065 and -G664C ANP gene SNPs and AF in a Caucasian population of patients with structural AF. Further studies will clarify whether these or other ANP gene variants affect the risk of different subphenotypes of AF driven by distinct pathophysiological mechanisms.
心房利钠肽（ANP）具有抗肥厚和抗纤维化特性，与房颤基质相关。-G664C和rs5065 ANP单核苷酸多态性（SNP）已被描述与包括高血压和左心室肥厚在内的临床表型相关。最近一项研究评估了低风险受试者中早期房颤与rs5065 SNP的关联。在一个具有中度至高度心血管风险特征且患有结构性房颤的白种人群中，我们进行了一项病例对照研究，以评估ANP -G664C和rs5065 SNP是否与非家族性结构性房颤相关。
招募了168例非家族性结构性房颤患者和168例年龄及性别匹配的对照。对rs5065和-G664C ANP SNP进行基因分型。
研究人群具有中度至高度心血管风险特征，86%患有高血压，23%患有糖尿病，26%有既往心肌梗死病史，23%有左心室收缩功能障碍。房颤患者的左心房直径更大（44±7 vs. 39±5 mm；P<0.001），血浆NTproANP水平更高（6240±5317 vs. 3649±2946 pmol/mL；P<0.01）。rs5065和-G664C基因变异的优势比（OR）分别为1.1（95%置信区间[CI]，0.7 - 1.8；P = 0.71）和1.2（95%CI，0.3 - 3.2；P = 0.79），表明与房颤无关联。-664C和rs5065次要等位基因变异的携带者和非携带者之间的基线临床特征无差异。
我们报告在患有结构性房颤的白种人群中，rs5065和-G664C ANP基因SNP与房颤之间缺乏关联。进一步研究将阐明这些或其他ANP基因变异是否会影响由不同病理生理机制驱动的房颤不同亚表型的风险。
